Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole in DCIS and Early Invasive Breast Cancer
NCT00256217Phase 2Completed
- Start
- Sep 2004
- Primary completion
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in ductal carcinoma in situ (DCIS) and breast cancer. Primary endpoint: Change in Ki-67 Level at 4 weeks. Started Sep 2004; status: completed.
02
Drugs
anastrozole
03
Conditions
ductal carcinoma in situ (DCIS)breast cancer
Beyond the preview
Go deeper on NCT00256217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256217.